AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20463104
Drug: HIV-1 DNA
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 DNA vaccine (intradermally or intramuscularly) with GM-CSF adjuvant, boosted with modified vaccinia virus Ankara (HIV-MVA) at 9 months
Trial: 10534036
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg of intravenous methyl prednisolone administered prehospital to asthma patients (11 patients in year 2)
Trial: 10534036
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patients who did not receive prehospital steroids)
Trial: 6353878
Drug: 0.075 mg
RxNorm normalized name: mestranol 0.075 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075 mg clonidine at 8 a.m. and 0.15 mg at 10 p.m.
Trial: 22985564
Drug: Nucleoside analogue
RxNorm normalized name: Nucleoside analogue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside analogue (NA) treatment
Trial: 24863037
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine gel
Trial: 10501818
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg per day
Trial: 23722352
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of 1% oestrone cream applied once daily for 24 weeks
Trial: 22704121
Drug: Periprostatic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic nerve block (2.5 ml of the same mixture) plus intrarectal local anesthesia (lidocaine 1.5%-nifedipine 0.3% cream)
Trial: 17296646
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (n = 109)
Trial: 11318078
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol solution twice daily
Trial: 9776370
Drug: Psychotropic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic medications and counseling (index group)
Trial: 3395668
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release pseudoephedrine suspension (CR)
Trial: 3395668
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release reference syrup (IR-Sudafed)
Trial: 28668671
Drug: Deutetrabenazine 36
RxNorm normalized name: deutetrabenazine 36 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine 36 mg/day
Trial: 28668671
Drug: Deutetrabenazine 24
RxNorm normalized name: deutetrabenazine 24 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine 24 mg/day
Trial: 15446505
Drug: Magnetocardiography (MCG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetocardiography (MCG) measurements in patients with ischemia
Trial: 15446505
Drug: Magnetocardiography (MCG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetocardiography (MCG) measurements in healthy controls
Trial: 9382207
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (lmw-heparin) at 1.5-5 IE/kg body weight per hour
Trial: 8103145
Drug: Octreotide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide infusion (50 micrograms intravenous bolus plus 50 micrograms per h intravenous infusion for 48 h)
Trial: 27030533
Drug: DHA-rich fish-oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish-oil capsules (800 mg DHA/d)
Trial: 27030533
Drug: Vegetable-oil capsules
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable-oil capsules (control group)
Trial: 25519880
Drug: Preventive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive chemotherapy with praziquantel (exact dosage and duration not specified)
Trial: 18230353
Drug: Acarbose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (100 mg x 3/day, group A)
Trial: 18230353
Drug: Glimepiride (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (2 mg/day, group G)
Trial: 15722313
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 20-25 mg of triamcinolone acetonide
Trial: 29512336
Drug: Temporary anchorage
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary anchorage devices (TADs) used in orthodontic treatment, including 50 (3M ESPE), 56 (Bone screw), and 74 (Morelli) TADs, with lengths of 6, 8, and 10 mm and diameters of 1.5, 1.6, and 1.8 mm, and force levels set at 50, 100, 150, 200, and 250 g.
Trial: 15076203
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg without active pretreatment (placebo)
Trial: 15076203
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg after 5 days' treatment with amiloride 5 mg twice daily
Trial: 15076203
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no active drugs)
Trial: 12536532
Drug: BZX treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZX treatment
Trial: 9286940
Drug: Fradafiban (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fradafiban (1 to 15 mg continuously infused over 30 minutes)
Trial: 9286940
Drug: Lefradafiban (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lefradafiban (single oral doses of 50 mg, 100 mg, and 150 mg)
Trial: 9286940
Drug: Lefradafiban (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lefradafiban (oral TID for 7 days)
Trial: 28682929
Drug: Rasagiline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline (1 mg)
Trial: 28682929
Drug: Safinamide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safinamide (50 mg or 100 mg)
Trial: 24309336
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at a dose of 2 to 2.5 mg/kg as induction dose and sedation maintained with 5 to 10 mg/min.
Trial: 20451972
Drug: No scalpel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No scalpel vasectomy with distal vasal flushing (30 mL of sterile water)
Trial: 19030713
Drug: Melatonin 3
RxNorm normalized name: melatonin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 3 mg, orally in a single dose, 1 hour before bedtime for 21 consecutive days
Trial: 8657519
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg rhSOD
Trial: 1724525
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of L + C vs L + GG
Trial: 16393213
Drug: Eradication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication treatment (group 1)
Trial: 10459447
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of urinary follicle‐stimulating hormone (FSH, Fostimon 75, A.M.S.A., Italy)
Trial: 10459447
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of urinary follicle‐stimulating hormone (FSH, Metrodin 75 HP, Serono, Italy)
Trial: 2719903
Drug: Buccal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal morphine
Trial: 28758717
Drug: EPA+DHA therapy
RxNorm normalized name: eicosapentaenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA+DHA therapy
Trial: 22084332
Drug: Dabigatran, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran, 150 mg or 110 mg twice daily
Trial: 15505965
Drug: Dual-route model
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-route model treatment
Trial: 15505965
Drug: Single-route model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-route model treatment
Trial: 3982903
Drug: Aminophylline plus
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline plus doxapram therapy
Trial: 29140864
Drug: 2.5 mL
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL 0.5% bupivacaine with 1:200,000 epinephrine (Group A)
Trial: 29140864
Drug: 2.5 mL
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL of 1% lidocaine with 1:100,000 epinephrine (Group B)
Trial: 24946636
Drug: Embedding therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embedding therapy on back‐shu points and front‐mu points and needle‐pricking therapy on Sifeng (EX‐UE 10)
Trial: 17500623
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR treatment
Trial: 12114418
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate (400 mg/day given p.o.)
Trial: 8026259
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg every other day (group C)
Trial: 2918132
Drug: Chlorhexidine varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine varnish (second treatment)
Trial: 26817306
Drug: Oral sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sertraline hydrochloride at 50 mg qd for 12 weeks
Trial: 15132126
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (single dose)
Trial: 9789694
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion (control group).
Trial: 145654
Drug: Administration by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by investigator
Trial: 145654
Drug: Self-administration by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration by patients
Trial: 21699587
Drug: 400 mL
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mL of oral supplement and dietary advice
Trial: 8110568
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% 40 ml with morphine 5 mg (group BM5)
Trial: 2761061
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (1.2 g)
Trial: 779054
Drug: Indoramin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin (mean dose: 158 ± 9 mg per day)
Trial: 779054
Drug: Methyldopa (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (mean dose: 1540 ± 90 mg per day)
Trial: 25908703
Drug: CPMHA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPMHA with lidocaine (BEL‐L)
Trial: 25908703
Drug: Control: CPMHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: CPMHA with lidocaine (BEL‐L)
Trial: 21226678
Drug: Zolpidem (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (5 mg)
Trial: 20178218
Drug: 16% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16% carbamide peroxide bleaching agent (Pola Night) for 2 hours a day for 3 weeks
Trial: 19088953
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no bleaching treatment)
Trial: 11689755
Drug: Triple sulfonamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple sulfonamide vaginal cream
Trial: 7696452
Drug: Budesonide retention
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide retention enema (2.3 mg/115 mL)
Trial: 14985932
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg zolpidem
Trial: 22767144
Drug: Docetaxel 60
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m² plus Irinotecan 250 mg/m² (Day 1)
Trial: 22767144
Drug: Docetaxel 85
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 85 mg/m² (Day 1) followed by 5-fluorouracil 750 mg/m² per day (Days 1-5)
Trial: 894973
Drug: Modified pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Modified pilocarpine solution
Trial: 894973
Drug: Pure pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pure pilocarpine solution
Trial: 17181400
Drug: Action Schools!
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action Schools! BC (AS! BC) intervention including a daily jumping program (Bounce at the Bell) plus 15 minutes/day of classroom physical activity.
Trial: 6294517
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous cyclophosphamide plus ACTH
Trial: 6294517
Drug: Plasma exchange,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange, low-dose oral cyclophosphamide, and ACTH
Trial: 31496674
Drug: Indacaterol (IND)
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol (IND) 150 μg q.d.
Trial: 31496674
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (TIO) 18 μg q.d.
Trial: 29945934
Drug: Newer-generation ultrathin
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer-generation ultrathin strut drug-eluting stents (strut thickness <70 µm)
Trial: 29945934
Drug: Thicker strut
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thicker strut second-generation drug-eluting stents
Trial: 1105692
Drug: Intra-amniotic PGF2alpha
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-amniotic PGF2alpha 40 mg
Trial: 16529667
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 400 microg every 4 hours (to a maximum of four doses)
Trial: 10480263
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied three times per week for up to 16 weeks
Trial: 8583605
Drug: 3-drug mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-drug mixture (17.64 mg/ml papaverine, 0.58 mg/ml phentolamine, 5.8 micrograms/ml prostaglandin E1)
Trial: 1918458
Drug: Tretinoin emollient
RxNorm normalized name: Tretinoin Emollient Topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin emollient 0.05% cream
Trial: 3950112
Drug: Vehicle therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle therapy
Trial: 26946148
Drug: Cumulative duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative duration of triple-low state (low MAP <65 mmHg, low BIS <45, low Ce <1.5 μg ml-1 of propofol anesthesia)
Trial: 21167689
Drug: Cognitive enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive enhancement therapy (CET)
Trial: 21629190
Drug: Probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic group (Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14 capsules)
Trial: 19443419
Drug: Lidocaine infusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine infusion (2 mg kg(‐1) h(‐1) during surgery and 1 mg kg(‐1) min(‐1) for the first 24 postoperative hours)
Trial: 11316241
Drug: i.v. Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. Fe alone (same dose as Group A)
Trial: 9396542
Drug: Biofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback therapy (2 to 8 sessions)
Trial: 7895957
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (experimental group, n = 16)
Trial: 7895957
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (control group, n = 5)
Trial: 27821210
Drug: Olanzapine 15
RxNorm normalized name: olanzapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 15 mg once daily
Trial: 27821210
Drug: Asenapine 2.5
RxNorm normalized name: asenapine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 2.5 mg bid
Trial: 27821210
Drug: Asenapine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine (both doses)
Trial: 22656044
Drug: Non-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-guided treatment (clopidogrel non-responders did not undergo any change in treatment)
Trial: 22656044
Drug: Non-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-guided treatment
Trial: 15249618
Drug: Women initiating
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women initiating hormones at older ages
Trial: 16413249
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg lansoprazole
Trial: 7770708
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lansoprazole
Trial: 3099028
Drug: Fosfomycin (FOM)
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin (FOM) otic solution
Trial: 30260372
Drug: iPad administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iPad administration of the Pattern Comparison Processing Speed Test
Trial: 30260372
Drug: iPad administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iPad administration of the Dimensional Change Card Sort Test
Trial: 30260372
Drug: iPad administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iPad administration of the List Sorting Working Memory Test
Trial: 15010697
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg plus titrated dose of yohimbine (F/Y)
Trial: 15010697
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg plus placebo (F/P)
Trial: 11379254
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prophylactic therapy, free to receive treatment or exercises)
Trial: 788907
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (DHE) 2 mg three times daily for 14 days
Trial: 18931211
Drug: 0.1 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mL/kg of 1% lidocaine with 1:200,000 epinephrine (0.5 mug/kg of epinephrine) IV
Trial: 12670779
Drug: Formoterol pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol pre-treatment + formoterol 18 microg
Trial: 11105736
Drug: Stepwise initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Stepwise initiation (a sequence of 1 week each on placebo; olanzapine, 5 mg q.d.; and olanzapine, 10 mg q.d.)
Trial: 11105736
Drug: Abrupt discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrupt discontinuation of prior antipsychotic drug
Trial: 11105736
Drug: Gradual discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual discontinuation of prior antipsychotic drug
Trial: 16899362
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg daily for the first 7 days, increased by 25 mg each week up to 150 mg
Trial: 16899362
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg daily for 21 days followed by a 7-day rest period, repeated for 3 cycles
Trial: 3927958
Drug: Nicardipine 30
RxNorm normalized name: niCARdipine 30 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 30 mg thrice daily
Trial: 3510823
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg thrice daily